30403-45-3

Basic information

• Product Name: 3-benzyl-1,2-dibutanoyl-sn-glycerol
• Synonyms: 3-benzyl-1,2-dibutanoyl-sn-glycerol
• CAS NO: 30403-45-3
• Molecular Weight: 322.401
• Mol File: 30403-45-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-benzyl-1,2-dibutanoyl-sn-glycerol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyl-1,2-dibutanoyl-sn-glycerol(30403-45-3)
• EPA Substance Registry System: 3-benzyl-1,2-dibutanoyl-sn-glycerol(30403-45-3)

Safety Data

• Hazardous Substances Data: 30403-45-3(Hazardous Substances Data)

Upstream product

• 13071-59-5 3-benzyloxypropan-1,2-diol 
• 141-75-3 butyryl chloride 
• 106-31-0 butanoic acid anhydride 
• 56552-80-8 (R)-3-benzyloxy-1,2-propanediol 
• 107-92-6 butyric acid 
• 123-20-6 vinyl n-butyrate 
• 793686-33-6 Butyric acid (R)-3-benzyloxy-2-hydroxy-propyl ester 
• 15028-56-5 4-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane 
• 100-44-7 benzyl chloride 

Downstream Products

• 30403-51-1 1,2-di-O-hexacecanoyl-3-O-benzyl-sn-glycerol 
• 56552-80-8 (R)-3-benzyloxy-1,2-propanediol 

Relevant articles and documents

COMPOUND, COMPOSITION AND USES THEREOF

The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI and formula VII or its pharmaceutical acceptable compositions and salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compositions or salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of stomach and esophageal problems or its associated complications.

Design, synthesis, and evaluation of water-soluble phospholipid analogues as inhibitors of phospholipase C from Bacillus cereus

The rate of hydrolysis of natural phospholipids by the phosphatidyleholine-preferring phospholipase C from Bacillus cereus (PLC Bc) follows the order phosphatidylcholine > phosphatidylethanolamine ? phosphatidyl-L-serine. To probe the structural basis for this substrate specificity, a series of water-soluble, nonhydrolyzable substrate analogues were needed so their complexes with the enzyme could be studied via X-ray crystallography and isothermal titration calorimetry (ITC). Accordingly the water-soluble dithiophospholipids 2-10 having choline, ethanolamine, and L-serine headgroups were synthesized, and the inhibitory activity of each was determined in an assay using 1,2-dihexanoyl-sn-glycero-3-phosphocholine (C6PC) as the monomeric substrate. The 1,2-dibutanoyl dithiophosphocholine 2 was a weak inhibitor, whereas the related 1,2-dipentanoyl dithiophospho-choline 3 and the ethylene glycol dithiophosphocholines 4 and 5 were moderate inhibitors. The 1,2-ω -hydroxydiacyl dithiophosphocholines 6 and 7 were potent inhibitors, while the related compound 8, which had shorter acyl side chains, was a weak inhibitor. The dithiophosphoethanolamine 9 was a modest inhibitor, whereas the dithiophospho-L-serine 10 was a somewhat weaker inhibitor. Overall, the phospholipid analogues had increasing Ki values according to the order 2 ? 10 3 4 ≈ 5 ≈ 8 9 ? 6 ? 7 and increasing solubility according to the sequence 5 ≈ 7 4 ≈ 6 ≈ 9 3 10 8 2.